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B cells play a pivotal role in autoimmunity not only by producing pathogenic autoantibodies but also by modulating
immune responses via the production of cytokines and chemokines. The B cell-activating factor/a proliferation-inducing
ligand (BAFF/APRIL) system promotes B cell survival and differentiation and thus plays a prominent role in the
pathogenesis of autoimmune diseases. Currently, BAFF and APRIL inhibitors are in clinical trials for systemic
lupus erythematosus with significant efficacy. However, several studies have demonstrated the efficacy of the
BAFF/APRIL blockade which showed considerable variability in the response to B cell-targeted therapy. This
may indicate substantial heterogeneity in the pathogenesis of autoimmune diseases. Therefore, objective
markers that can predict the effect of BAFF/APRIL-blocking agents could be valuable to the precision
medicine linked clinically and to cost-effective therapy.
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Systemic autoimmune diseases are pathologically charac-
terized by immune complexes consisting of antigens, the
activation of dendritic cells and autoreactive T cells, and
the overproduction of autoantibodies secreted from
activated B cells, which cause severe inflammation in
various organs [1]. Although the survival of patients with
autoimmune diseases has improved over the past
50 years with conventional treatments such as immuno-
suppressants and corticosteroids, these drugs are limited
by inefficacy and intolerance in some patients. Since sev-
eral autoimmune diseases such as systemic lupus erythe-
matosus (SLE) and ANCA-associated vasculitis (AAV)
remain an important cause of mortality and morbidity,
innovative therapeutic approaches need to be developed.
B cells play a pivotal role in the pathogenesis of
autoimmune diseases not only by producing patho-
genic autoantibodies but also by modulating immune
responses via production of cytokines and chemokines
[2]. The potential efficacy of B cell depletion therapy
has been reported in several autoimmune diseases. Ri-
tuximab, a chimeric anti-CD20 antibody, eliminates* Correspondence: tanaka@med.uoeh-u.ac.jp
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stated.CD20-expressing pre-B and mature B cells through
antibody- and complement-dependent cytotoxic activ-
ities [3]. In Japan, rituximab is approved for clinical
use in childhood refractory nephrotic syndrome and
AAV such as granulomatosis with polyangiitis (GPA)
and microscopic polyangiitis (MPA). Despite expectations,
large randomized controlled clinical trials of rituximab for
non-renal and renal SLE (EXPLORER and LUNAR,
respectively) did not achieve the primary goal [4, 5]. In
addition, adverse reactions such as hepatitis B virus reacti-
vation, opportunistic infections, malignancies, and ineffi-
cacy in AAV patients who were treated with rituximab
have been reported in a Japanese cohort (RiCRAV) [6].
Currently, the TNF family ligands, B cell-activating
factor (BAFF), a proliferation-inducing ligand (APRIL),
and those receptors (BAFF receptor (BAFF-R), trans-
membrane activator and calcium modulator and cyto-
philin ligand interactor (TACI), B cell maturation
antigen (BCMA), and proteoglycans) are found to play
a prominent role in the pathogenesis of and are known
as the potential therapeutic target for autoimmune dis-
eases. In this review, we highlight the recent advance in
the BAFF/APRIL-targeted therapy in systemic auto-
immune diseases.ss This article is distributed under the terms of the Creative Commons
ativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution,
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between B cells and Tfh cells
Disturbances of T cell and B cell functions are involved in
the development of autoimmune diseases [2, 7–11]. Acti-
vated B cells function as potent antigen-presenting cells
and activate autoreactive T cells. The expression of co-
stimulatory molecules, such as CD40 and CD80, is
enhanced on B cells in autoimmune diseases such as SLE
and is involved in the interactive activation with surround-
ing immunocompetent cells including autoreactive T cells
[8, 9]. In addition, RNA- or DNA-containing autoanti-
gens co-ligate B cell receptors (BCRs) and Toll-like
receptor (TLR)-7/9, leading to robust activation, prolif-
eration, and differentiation of autoreactive B cells [12].
In SLE, autoantibodies produced by autoreactive B cells
form immune complexes that deposit in tissues, leading
to persistent inflammation and organ damage. Further-
more, it is well known that the number of memory B
cells and plasmablasts correlate with disease activity in
SLE [13–15]. We reported previously that the propor-
tions of CD19+IgD−CD27+ class-switched memory B
cells and CD19+IgD−CD27− effector memory B cells
tended to be higher in the peripheral blood of refrac-
tory SLE patients than in that of the control [16–18]. In
contrast, B regulatory (Breg) cells, which produce inter-
leukin (IL)-10 and transforming growth factor-β (TGF-
β) and suppress effector T cells, are defective in patients
with SLE [19].
The differentiation of CD4+ T helper cells into func-
tionally distinct helper T subsets is critical for the patho-
genesis of autoimmune diseases [20, 21], especially since
the active involvement of T helper (Th) 17 and T follicu-
lar helper (Tfh) cells and the dysfunction of T regulatory
(Treg) cells have been reported [20, 22–27]. Among
these subsets, the Tfh cells have emerged as a critical
regulator of autoimmunity [22]. The Tfh cells provide B
cell help by promoting the class switching of B cells and
are defined by the expression of the master regulator
Bcl6 and effector cytokine IL-21, along with key surface
molecules, such as PD-1, CXCR5, CD40L, and ICOS
[22, 28]. The CXCR5 expression allows Tfh cells to mi-
grate from the T cell zone to the B cell follicle where
they localize in the germinal center (GC) and mediate B
cell help via cell-cell contact using the co-stimulatory
molecules CD40L and ICOS [22]. Thus, B-Tfh cell inter-
action is necessary for autoantibody production. In mice,
the excessive activity of Tfh cells induces hyperactive
GC formation and autoantibody production, leading to a
SLE-like phenotype [29, 30]. While we and others have
reported the mechanism of Tfh differentiation, the exact
role of this subset in patients remains elusive. High pro-
portions of circulating Tfh cells, which are characterized
as CD4+CXCR5+ICOShighPD-1high, have been described
in SLE patients, and their level in the peripheral bloodcorrelates with titers of autoantibodies and with disease
severity [31, 32].
Taken together, these findings highlight the notion that
activated T cells, in addition to activated B cells, may also
be potentially involved in the pathogenesis of autoimmun-
ity and that the interaction between activated B and Tfh
cells may play an important role in autoantibody-driven
autoimmune diseases.
Pathological role of BAFF and APRIL in autoimmune
diseases
BAFF, also called B lymphocyte stimulator (BLyS), is a B
cell activation factor which is mainly expressed by mono-
cytes, macrophages, and activated T cells. BAFF can be
expressed on the cell surface as a membrane-bound form
or released as a soluble form after cleavage by furin. BAFF
binds to three receptors, the BAFF-R, BCMA, or TACI,
and regulates B cell survival, differentiation, maturation,
immunoglobulin class switching, and antibody production
(Fig. 1) [33, 34]. BAFF-R is mainly expressed in immature
B cells, whereas TACI and BCMA are expressed in
matured memory B cells and plasma cells, respectively. In
addition, APRIL, which is a homologous factor to BAFF,
binds to TACI, BCMA, and proteoglycans (Fig. 1). APRIL
forms heterotrimers with BAFF and enhances BAFF-
mediated B cell activation [35]. TACI binds with higher
affinity to APRIL but lower affinity to BAFF, compared
with other BAFF receptors. Although both BAFF and
APRIL promote B cell survival and differentiation, there
are complicated regulatory mechanisms according to
the varieties of the receptors (BAFF-R, BCMA, or
TACI) and the differentiation stage of B cells, as de-
scribed above. In addition to its effect on B cells, recent
works have demonstrated that BAFF can promote T cell
activation, proliferation, and differentiation [36]. Inter-
estingly, Coquery et al. reported that BCMA negatively
regulates Tfh cell expansion, while BAFF-R-mediated
signaling promotes Tfh cell accumulation into GC in
lupus-prone mice [37]. Thus, the balance between
BCMA and BAFF-R signaling may control the develop-
ment of Tfh cells, indicating that BAFF/APRIL regulate
autoimmunity not only via survival and differentiation
of B cell but also via expansion of Tfh cells.
Animal studies have shown that BAFF-deficient mice lack
B cell maturation and the knockout of BAFF in lupus-
prone mice showed a reduction of mortality and disease
severity [38]. The transgenic mice for BAFF show an ex-
panded B cell maturation and develop severe SLE, which is
supported by evidence on increased concentrations of anti-
double-stranded DNA (dsDNA) antibodies and immune
complex deposition in the mesangium [34, 39–41]. In
humans, the serum level of BAFF and APRIL is both ele-
vated in patients with SLE and positively correlates with
disease activity and serological markers such as anti-
Fig. 1 Emerging B cell-targeted therapy including BAFF/APRIL inhibition in autoimmune diseases. Current strategies for autoimmune diseases
include appropriate targets for therapeutic modulation such as B cell surface antigens (CD20 and CD22), co-stimulatory molecules (CTLA-4, CD40/
CD40L, ICOS/ICOSL, and BAFF/APRIL/BAFF-R/BCMA/TACI), and various intracellular signal transduction pathways (Syk and Btk)
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tween BAFF levels and circulating autoantibody levels in
Sjogren’s syndrome (SS) [44]. In addition, BAFF has been
found to be elevated in the serum of AAV patients [45, 46].
These results suggest a potential therapeutic strategy for
patients with systemic autoimmune diseases by BAFF and/
or APRIL blockade.
Targeting BAFF and APRIL in systemic autoimmune
diseases
1. BAFF blockers
Current strategies for autoimmune diseases include ap-
propriate targets for therapeutic modulation such as B cell
surface antigens (CD20 and CD22), co-stimulatory mole-
cules (CTLA-4, CD40/CD40L, ICOS/ICOSL, and BAFF/
APRIL/BAFF-R/BCMA/TACI), and various intracellular
signal transduction pathways (Syk and Btk) (Fig. 1)
[47, 48]. Selective inhibitors of BAFF and APRIL,
which should ameliorate the pathogenesis by inhibit-
ing autoreactive B cell activation and autoantibody
production, are in clinical trials for autoimmune dis-
eases (Fig. 1).
Belimumab is a fully human monoclonal antibody that
antagonizes BAFF, thus inhibiting B cell survival anddifferentiation [49]. Belimumab directly reduces activa-
tion of naïve and transitional B cells and indirectly inhibits
development of IgD−CD27+ class-switched memory B
cells, plasmablasts, and plasma cells. The multicenter, ran-
domized placebo-controlled double-blind phase III trials,
BLISS-52 and BLISS-76, were performed to investigate
the efficacy of belimumab at 1 or 10 mg/kg compared to
placebo in the treatment of active SLE [50–52]. The pri-
mary end point was amelioration in SRI (SLE responder
index), a composite measurement of SELENA-SLEDAI
(Safety of Estrogens in Lupus Erythematosus National
Assessment-Systemic Lupus Erythematosus Disease Activ-
ity Index), BILAG (British Isles Lupus Assessment Group)
score, and physician global assessment. The BLISS-52 trial
demonstrated that SRI rates at 52-week posttreatment
were 44 %, 51 % (p = 0.01), and 58 % (p < 0.01) in the pla-
cebo, belimumab 1 mg/kg, and belimumab 10 mg/kg
groups, respectively, suggesting a significant improvement
of disease activity with an increased dose of this drug [51].
Belimumab has greater therapeutic benefit in patients with
higher disease activity (SLEDAI ≥10), anti-dsDNA positiv-
ity, or low complement [53]. No significant difference
between the frequency of serious adverse reactions be-
tween the belimumab group and the placebo group was
observed. Collectively, these results highlighted the effi-
cacy and tolerability of belimumab as a novel biologic
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drug in 2011. However, the patients with active lupus
nephritis were excluded in these trials. Therefore, it would
be useful to investigate in future trials to elucidate the effi-
cacy of belimumab in the patients with major organ in-
volvements. Currently, the phase III trials to examine the
efficacy and safety of belimumab in active lupus nephritis
(NCT01639339) and in SLE patients located in Northeast
Asia (NCT01345253) are ongoing.
Furthermore, belimumab is currently undergoing
clinical trials in SS and AAV. In the phase II trial in 30
patients with primary SS (BELISS), 60 % of the pa-
tients were responders and systemic activity scores
measured by the EULAR SS disease activity index
(ESSDAI) were significantly improved [54, 55]. Since
this is an open-label trial, further randomized controlled
trials are warranted. The phase III multicenter, random-
ized, double-blind study to evaluate the efficacy and safety
of belimumab in combination with azathioprine for the
maintenance of remission in GPA and MPA (BREVAS) is
ongoing (NCT01663623) [56, 57].
Other anti-BAFF agents, tabalumab and blisibimod,
are also being assessed in phase III randomized
placebo-controlled trials to evaluate their efficacy in
SLE. Tabalumab is a monoclonal antibody that neu-
tralizes BAFF in both membrane-bound form and
soluble form, whereas belimumab is thought to target
the soluble form only. In rheumatoid arthritis (RA),
tabalumab showed clinical efficacy in phase II trials in pa-
tients with an inadequate response to methotrexate
(MTX) [58, 59]. However, the phase III trial demon-
strated that tabalumab did not provide the degree of
clinical efficacy in moderate-severe RA, taking the
MTX observed with other approved biological agents
[60]. Based on these findings, the pharmaceutical
company discontinued the phase III trial for RA. In
addition, the phase III clinical trials for tabalumab in
moderate to severe SLE (ILLUMINATE-2) met its pri-
mary end point only at higher doses but failed to meet
secondary end points [61]. The pharmaceutical company
also discontinued the development of this drug for SLE.
Blisibimod is a human “peptibody,” which binds to
both cell membrane-expressed and soluble BAFF and
antagonizes BAFF, and has recently been evaluated in a
phase II clinical trial (PEARL-SC) [62]. In this study, the
significant reductions in proteinuria and anti-dsDNA
and significant increases in C3 were observed with the
blisibimod group. Currently, a phase III study to exam-
ine the efficacy and safety of blisibimod in patients with
active SLE (NCT01395745) is under way.
Briobacept, a protein containing both IgG and the ligand
of BAFF-R, which antagonizes BAFF did not show suffi-
cient efficacy in a phase II trial (ATLAS) (NCT01499355)
and was terminated.2. TACI-Ig: atacicept
Atacicept, a recombinant fusion protein containing both
the Fc portion of the human IgG1 and the extracellular
domain of TACI [63, 64], binds to APRIL and BAFF and
inhibits activation of TACI-mediated signaling. The phase
I trial in moderately active SLE showed that atacicept re-
sulted in a 60 % reduction in mature B cells and a 45 %
attenuation of immunoglobulin compared to placebo [65].
There were no significant differences in the levels of ad-
verse reactions between atacicept and placebo. However,
the phase II clinical trial in patients with active lupus
nephritis who are taking steroids and MMF was termi-
nated due to severe infection [66]. Isenberg et al. reported
recently the results of a randomized phase II/III trial of
atacicept that sought to determine the efficacy and safety
of atacicept in the prevention of flares in SLE [67]. The
results with a high dose of atacicept were encouraging,
but there are severe concerns about the infections. Cur-
rently, the phase III clinical trials for atacicept in patients
who have no major organ involvements (ADDRESS II)
(NCT01972568, NCT02070978) are under way. In Japan,
a phase IIb trial in patients with SLE is in progress.
Conclusions
BAFF and APRIL play a prominent role in the pathogenesis
of autoimmune diseases. Indeed, a certain number of pa-
tients receive benefit from BAFF/APRIL-blocking therapies.
On the other hand, several clinical trials have demonstrated
the efficacy of the BAFF/APRIL blockade which showed
considerable variability in the response to B cell-targeted
therapy. Furthermore, increasing evidence points to sub-
stantial heterogeneity in the pathogenesis of autoimmune
diseases; thus, B cell-targeted therapy may be ineffective in
some patients but effective in others. Therefore, objective
markers that can predict the effect of BAFF/APRIL-block-
ing agents should be valuable to the precision medicine
linked clinically and to cost-effective therapy.
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